Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Issues related to prescription drug pricing; Issues related to World Trade Organization IP waiver; Issues related to pharmaceutical intellectual property; Issues related to international trade.
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines.
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Duration: March 26, 2019
to
present
General Issues: Health Issues , Medicare/Medicaid , Trade (Domestic & Foreign) , Budget/Appropriations , Copyright/Patent/Trademark , Taxation/Internal Revenue Code
Spending: about $1,020,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Derrick White
Deputy Communications Director, Senator Orrin Hatch
Jeff Forbes
Staff Director, Senate Finance Committee; Chief of Staff, Senator Max Baucus; Deputy Asst., Special Asst., Deputy Director EOP.
Libby Greer
Chief of Staff, Rep. Allen Boyd
Cindy Brown
Leg Assistant, Rep. Stupak, 1993-1994; Leg Director, Rep. Kind, 1999-2002; Chief of Staff, Rep. Kind, 2003-2009
Francesca McCrary
Legislative Assistant, Elijah Cummings (2016-2017); Professional Staff, House Oversight Reform Committee (2016-2016)
Jeff Strunk
Deputy Floor Director, House Speaker Boehner; Floor Assistant, House Speaker Boehner; Legislative Assistant, John Boehner; Staff Member, Pat Tiberi
Deputy Floor Director, Speaker John Boehner (2010-2013); Floor Assistant, House Speaker John Boehner (2007-2010); Legislative Assistant, Rep. John Boehner (2006 -2010); Staff Member, Rep. Pat Tiberi (2004-2006)
Kristina Dunklin
Legislative Director, Rep. Brooks, 2018 - 2019; Legislative Director, rep. Valadao, 2015-2018; Legislative Assistant, Rep. Valadao, 2014-2015
Jeff Sadosky
Communications Director, Senator Rob Portman; Communications Director, Senator Kay Bailey Hutchison; Deputy Press Secretary, Senator Mike DeWine
Communications Director, Sen. Rob Portman (2010-2013); Communications Director, Sen. Kay Bailey Hutchison (2008-2010); Press Secretary, Sen. Mike DeWine (2005-2006)
Barrett Thornhill
Legislative Assistant, Sen. Mike Crapo (2003-2006); Legislative Assistant, Rep. Pat Toomey (2002-2003); Legislative Assistant, Rep. Charlie Norwood (2001-2002)
Michael Williams
Williams, MichaelLegislative Director, Rep. Lucy McBath (2021-2022); Legislative Assistant, Rep. Lucy McBath (2019-2020); Legislative Aide, Sen. Brian Jones (2019); Legislative Correspondent, Sen. Brian Jones (2018-2019)
ED RENO
n/a
Zach Williams
n/a
Edward Reno III
n/a
Edward Reno III
n/a
Zachary Williams
n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, Forbes-Tate lobbied for Novartis, Inc. , earning $50,000. The report was filed on April 15.
Original Filing: 301550065.xml
Lobbying Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2024 (PL 118-42); Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing; Issues related to World Trade Organization IP waiver; Issues related to pharmaceutical intellectual property; Issues related to international trade.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2023
In Q4, Forbes-Tate lobbied for Novartis, Inc. , earning $50,000. The report was filed on Jan. 16.
Original Filing: 301525714.xml
Lobbying Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to COVID 19 funding for BARDA; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169). S.4348. - FDASLA Act of 2022 (117th Congress), S.4535 - FDASRA Act of 2022 (117th Congress), H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs (117th Congress); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers; H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing; Issues related to World Trade Organization IP waiver; Issues related to pharmaceutical intellectual property; Issues related to international trade.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2023
In Q3, Forbes-Tate lobbied for Novartis, Inc. , earning $50,000. The report was filed on Oct. 17, 2023.
Original Filing: 301503260.xml
Lobbying Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program; Issues related to the implementation of Consolidated Appropriations Act, 2022 (PL 117-103); Issues related to COVID 19 funding for BARDA; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169). S.4348. - FDASLA Act of 2022 (117th Congress), S.4535 - FDASRA Act of 2022 (117th Congress), H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs (117th Congress).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to pharmacy benefit managers.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing; Issues related to World Trade Organization IP waiver; Issues related to pharmaceutical intellectual property; Issues related to international trade.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to prescription drug pricing; Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to implementation of the Inflation Reduction Act of 2022 (PL 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2023
In Q2, Forbes-Tate lobbied for Novartis, Inc. , earning $50,000. The report was filed on July 16, 2023.
Original Filing: 301477054.xml
Lobbying Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to the implementation of H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). S.4348. - FDASLA Act of 2022 (117th Congress), S.4535 - FDASRA Act of 2022 (117th Congress), H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs (117th Congress).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing; issues related to World Trade Organization IP waiver; issues related to pharmaceutical intellectual property; issues related to international trade.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2023
In Q1, Forbes-Tate lobbied for Novartis, Inc. , earning $50,000. The report was filed on April 19, 2023.
Original Filing: 301456453.xml
Lobbying Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to the implementation of H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). S.4348. - FDASLA Act of 2022 (117th Congress), S.4535 - FDASRA Act of 2022 (117th Congress), H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs (117th Congress).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing; issues related to World Trade Organization IP waiver; issues related to pharmaceutical intellectual property; issues related to international trade.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2022
Forbes-Tate amended a lobbying report for representation of Novartis, Inc. in Q42022 on Jan. 26, 2023.
Original Filing: 301445064.xml
Lobbying Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). S.4348. - FDASLA Act of 2022, S.4535 - FDASRA Act of 2022, H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing; issues related to World Trade Organization IP waiver; issues related to pharmaceutical intellectual property; issues related to international trade.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instruction to Committees; COVID 19 therapeutic funding; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Issues related to implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2022
In Q4, Forbes-Tate lobbied for Novartis, Inc. , earning $50,000. The report was filed on Jan. 14, 2023.
Original Filing: 301427669.xml
Lobbying Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). S.4348. - FDASLA Act of 2022, S.4535 - FDASRA Act of 2022, H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing; issues related to World Trade Organization IP waiver; issues related to pharmaceutical intellectual property; issues related to international trade.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instruction to Committees; COVID 19 therapeutic funding; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
International Tax issues related to continued conversations on H.R. 5376 - Build Back Better Act: GILTI, BEAT, Corporate Minimum Tax; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2022
In Q3, Forbes-Tate lobbied for Novartis, Inc. , earning $50,000. The report was filed on Oct. 17, 2022.
Original Filing: 301405340.xml
Lobbying Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). S.4348. - FDASLA Act of 2022, S.4535 - FDASRA Act of 2022, H.R.7658 - To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships, provisions regarding reauthorization of FDA User Fee Programs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing; issues related to World Trade Organization IP waiver; issues related to pharmaceutical intellectual property; issues related to international trade.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instruction to Committees; COVID 19 therapeutic funding; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
International Tax issues related to continued conversations on H.R. 5376 - Build Back Better Act: GILTI, BEAT, Corporate Minimum Tax; Issues related to consideration and passage of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2022
Forbes-Tate amended a lobbying report for representation of Novartis, Inc. in Q22022 on July 19, 2022.
Original Filing: 301386911.xml
Lobbying Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing; issues related to World Trade Organization IP waiver; issues related to pharmaceutical intellectual property; issues related to international trade.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instruction to Committees; COVID 19 therapeutic funding.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
International Tax issues related to continued conversations on H.R. 5376 - Build Back Better Act: GILTI, BEAT, Corporate Minimum Tax.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2022
In Q2, Forbes-Tate lobbied for Novartis, Inc. , earning $50,000. The report was filed on July 17, 2022.
Original Filing: 301382045.xml
Lobbying Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022; Issues related to COVID 19 funding for BARDA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing; issues related to World Trade Organization IP waiver; issues related to pharmaceutical intellectual property; issues related to international trade.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instruction to Committees; COVID 19 therapeutic funding.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2022
Forbes-Tate amended a lobbying report for representation of Novartis, Inc. in Q12022 on April 21, 2022.
Original Filing: 301372682.xml
Lobbying Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing; issues related to World Trade Organization IP waiver; issues related to pharmaceutical intellectual property; issues related to international trade.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instruction to Committees; COVID 19 therapeutic funding.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2022
In Q1, Forbes-Tate lobbied for Novartis, Inc. , earning $50,000. The report was filed on April 17, 2022.
Original Filing: 301357805.xml
Lobbying Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues regarding the 340B Drug Pricing Program Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees; Issues related to H.R.2471 - Consolidated Appropriations Act, 2022.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instruction to Committees.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to prescription drug pricing; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instruction to Committees.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2021
In Q4, Forbes-Tate lobbied for Novartis, Inc. , earning $50,000. The report was filed on Jan. 16, 2022.
Original Filing: 301323466.xml
Lobbying Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues related to drug pricing and Section 340B of the Public Health Service Act; Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instruction to Committees.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instruction to Committees.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2021
In Q3, Forbes-Tate lobbied for Novartis, Inc. , earning $50,000. The report was filed on Oct. 18, 2021.
Original Filing: 301301874.xml
Lobbying Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues related to drug pricing and Section 340B of the Public Health Service Act; Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instruction to Committees.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instruction to Committees.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines; Issues related to House and Senate FY 22 Budget Resolution (S. Con Res. 14) and resulting Budget Reconciliation Instructions to Committees.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2021
In Q2, Forbes-Tate lobbied for Novartis, Inc. , earning $50,000. The report was filed on July 17, 2021.
Original Filing: 301278513.xml
Lobbying Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues related to drug pricing and Section 340B of the Public Health Service Act; Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medicare/Medicaid Budget/Appropriations
Lobbying Issues
Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2); Issues regarding the World Trade Organization's TRIPS Waiver on COVID Vaccines.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2021
In Q1, Forbes-Tate lobbied for Novartis, Inc. , earning $50,000. The report was filed on April 17, 2021.
Original Filing: 301255111.xml
Lobbying Issues
Issues related to prescription drug pricing; Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues related to drug pricing and Section 340B of the Public Health Service Act; Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medicare/Medicaid Budget/Appropriations
Lobbying Issues
Issues related to prescription drug pricing; Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Issues related to prescription drug pricing and Intellectual Property (IP); Issues regarding H.R. 1319 - American Rescue Plan Act of 2021 (Public Law No: 117-2).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2020
In Q4, Forbes-Tate lobbied for Novartis, Inc. , earning $50,000. The report was filed on Jan. 19, 2021.
Original Filing: 301236289.xml
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136); Issues related to drug pricing and Section 340B of the Public Health Service Act; Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign) Copyright/Patent/Trademark
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136); Issues related to H.R. 925 - The Heroes Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2020
In Q3, Forbes-Tate lobbied for Novartis, Inc. , earning $50,000. The report was filed on Oct. 18, 2020.
Original Filing: 301212881.xml
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136); Issues related to drug pricing and Section 340B of the Public Health Service Act; Issues dealing with House Oversight and Reform Drug Pricing Investigation and Hearings.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign) Copyright/Patent/Trademark
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136); Issues related to H.R. 925 - The Heroes Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2020
In Q2, Forbes-Tate lobbied for Novartis, Inc. , earning $50,000. The report was filed on July 18, 2020.
Original Filing: 301192941.xml
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to Medicare, Medicaid, Cell and Gene Therapies; Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medicare/Medicaid Budget/Appropriations
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to H.R. 748 - the CARES Act (Pub.L. 116-136).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign) Copyright/Patent/Trademark
1st Quarter, 2020
In Q1, Forbes-Tate lobbied for Novartis, Inc. , earning $50,000. The report was filed on April 20, 2020.
Original Filing: 301174020.xml
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to Medicare, Medicaid, Cell and Gene Therapies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medicare/Medicaid Budget/Appropriations
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign) Copyright/Patent/Trademark
4th Quarter, 2019
In Q4, Forbes-Tate lobbied for Novartis, Inc. , earning $50,000. The report was filed on Jan. 20, 2020.
Original Filing: 301122639.xml
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to Medicare, Medicaid, Cell and Gene Therapies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medicare/Medicaid Budget/Appropriations
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign) Copyright/Patent/Trademark
3rd Quarter, 2019
In Q3, Forbes-Tate lobbied for Novartis, Inc. , earning $50,000. The report was filed on Oct. 20, 2019.
Original Filing: 301072415.xml
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP); Issues related to Medicare, Medicaid, Cell and Gene Therapies.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medicare/Medicaid Budget/Appropriations
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign) Copyright/Patent/Trademark
2nd Quarter, 2019
In Q2, Forbes-Tate lobbied for Novartis, Inc. , earning $50,000. The report was filed on July 21, 2019.
Original Filing: 301053828.xml
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Health Issues Trade (Domestic & Foreign)
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), and Intellectual Property (IP).
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medicare/Medicaid Budget/Appropriations
1st Quarter, 2019
In Q1, Forbes-Tate lobbied for Novartis, Inc. , earning $20,000. The report was filed on April 22, 2019.
Original Filing: 301035122.xml
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Type of Issue
Medicare/Medicaid Budget/Appropriations
Lobbying Issues
Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2019
Forbes-Tate filed a lobbying registration on April 1, 2019 to represent Novartis, Inc., effective March 26, 2019.
Original Filing: 301022161.xml
Issue(s) they said they’d lobby about: Issues related to prescription drug pricing, the United States-Mexico-Canada Agreement (USMCA), FY 2020 appropriations. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate